Journal
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
Volume 37, Issue 11, Pages 1331-1336Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/ice.2016.188
Keywords
-
Funding
- Pfizer
Ask authors/readers for more resources
OBJECTIVE. To examine attributable mortality and costs of Clostridium difficile infection (CDI) in the Medicare population. DESIGN. A population-based cohort study among US adults aged at least 65 years in the 2008-2010 Medicare 5% sample, with follow-up of 12 months. PATIENTS. Incident CDI episode was defined by the International Classification of Diseases, Ninth Revision, Clinical Modification code of 008.45 and no other occurrences within the preceding 12 months. To quantify the adjusted mortality and costs we developed a 1:1 propensity matched sample of CDI and non-CDI patients. RESULTS. Among 1,165,165 patients included, 6,838 (0.6%) had a CDI episode in 2009 (82.5% healthcare-associated). Patients with CDI were older (mean [SD] age, 81.0 +/- 8.0 vs 77.0 +/- 7.7 years, P < .001), were more likely to come from the Northeast (27.4% vs 18.6%, P < .001), and had a higher comorbidity burden (Charlson score, 4.6 +/- 3.3 vs 1.7 +/- 2.1, P < .001). Hospitalizations (63.2% vs 6.0%, P < .001) and antibiotics (33.9% vs 12.5%, P < .001) within the prior 90 days were more common in the group with CDI. In the propensity-adjusted analysis, CDI was associated with near doubling of both mortality (42.6% vs 23.4%, P < .001) and total healthcare costs ($64,807 +/- $66,480 vs $38,128 +/- $46,485, P < .001). CONCLUSIONS. Among elderly patients, CDI is associated with an increase in adjusted mortality and healthcare costs following a CDI episode. Nationwide annually this equals 240,000 patients with CDI, 46,000 potential deaths, and more than $6 billion in costs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available